Role of high‑sensitivity C‑reactive protein in patients with sarcoma
- Ninna Aggerholm‑Pedersen
- Thomas Baad‑Hansen
- Holger Jon Møller
- Birgitte Sandfeld‑Paulsen
Affiliations: Department of Experimental Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark, Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark
- Published online on: October 30, 2023 https://doi.org/10.3892/ol.2023.14118
Copyright: © Aggerholm‑Pedersen
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Immunotherapy has shown promising results in lung cancer and melanomas; however, the responses have been poor in patients with sarcoma. Understanding the relationship between the immune system and sarcoma is essential to develop improved immunotherapy approaches. High‑sensitivity C‑reactive protein (hs‑CRP) has been proposed as a prognostic marker in other cancer types; however, to the best of our knowledge, the association between hs‑CRP levels and mortality in patients with sarcoma has not been investigated. The present prospective, non‑randomised, non‑interventional explorative study investigated the prognostic value of hs‑CRP in patients with sarcoma. Patients referred to the sarcoma centre of Aarhus University Hospital (Aarhus, Denmark) were included between April 2014 and December 2020. Clinical data were obtained from the national quality sarcoma database and biomarkers other than hs‑CRP were obtained from the clinical laboratory information system. The study cohort consisted primarily of patients with localised sarcoma. hs‑CRP was significantly higher in patients with bone sarcoma (P=0.022) and soft tissue sarcoma (STS; P<0.001) compared with control patients. For STS, grade III tumours but not metastatic disease were associated with a higher hs‑CRP level (P=0.0001). Elevated hs‑CRP levels were associated with increased overall mortality [hazard ratio (HR), 1.91; 95% CI, 1.33‑2.75; P=0.001]. Furthermore, elevated hs‑CRP levels were also associated with decreased progression‑free survival (HR, 1.64; 95% CI, 1.17‑2.29; P=0.004). Furthermore, for patients with hs‑CRP <8 mg/l, higher hs‑CRP was associated with an increased risk of recurrent disease and reduced overall survival compared with those of patients with low hs‑CRP. In conclusion, the present study demonstrated that hs‑CRP was a prognostic factor for overall mortality and progression‑free survival in patients with localised sarcoma at the time of diagnosis. Further studies are required to investigate the mechanism behind the association between hs‑CRP and sarcoma prognosis and its potential use in clinical practice.